Kodiak Sciences Business Summary

Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company that operates on a research-and-development-heavy business model, currently generating no product revenue as it advances its proprietary Antibody Biopolymer Conjugate (ABC) platform. The company’s primary business segments focus on high-prevalence retinal vascular diseases—including neovascular wet age-related macular degeneration (wet AMD), diabetic retinopathy, and retinal vein occlusion—and inflammatory retinal conditions like macular edema secondary to inflammation (MESI). Kodiak’s value proposition centers on its "science of durability," aiming to disrupt the $15 billion anti-VEGF market by reducing the frequency of intravitreal injections compared to current standards of care. It competes directly with industry giants such as Regeneron Pharmaceuticals (Eylea), Roche/Genentech (Vabysmo), and AbbVie, positioning itself as a high-risk, high-reward innovator seeking to establish a dominant retinal franchise through superior long-interval dosing. Kodiak was co-founded in 2009 by Chairman and CEO Victor Perlroth, M.D., who previously served as a Venture Partner at MPM Capital and co-founded Avidia Inc. (acquired by Amgen). The executive leadership team includes CFO John Borgeson, a 25-year veteran of Pfizer, and Chief Scientific Officer Dolly Chang, alongside Senior Vice President of Discovery Medicine Hong Liang, Ph.D., also formerly of Pfizer’s Rinat Laboratory. The company is backed by high-profile institutional investors, most notably Baker Bros. Advisors LP, whose managing member Felix J. Baker, Ph.D., serves on the board. Other prominent board members include Charles Bancroft, former CFO of Bristol-Myers Squibb, and Taiyin Yang, Ph.D., former Executive Vice President at Gilead Sciences, providing the firm with deep clinical, manufacturing, and financial expertise as it approaches pivotal Phase 3 data readouts and its inaugural BLA filing in 2026.